What question did this study set out to answer?

April 24, 2026Open Access

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

MOMINNA B. OLSENZealand Pharma (Denmark)JGJON GRIFFINZealand Pharma (Denmark)UHUlrike HövelmannProfil Institute for Metabolic Research

Key Points

This research aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management.
Conducted two randomized, controlled Phase 1 trials.
Evaluated the incidence of gastrointestinal adverse events (TEAEs) and weight loss outcomes.
Analyzed pharmacokinetics and pharmacodynamics of petrelintide.
Petrelintide was found to be safe with a low incidence of gastrointestinal adverse events.
Participants experienced clinically relevant weight loss with the medication.
Findings suggest improved gastrointestinal tolerability compared to current therapies.

Abstract

Petrelintide appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss. These findings support further development of petrelintide as an effective weight-management medication, with potential for improved GI tolerability over existing therapies.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper